NCT05128734
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Chemotherapy, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients that have not had at least one line of chemotherapy (anthracyclines & taxanes) in the context of metastatic disease; Prior treatment with Temodar/temozolomide or Lynparza/olaparib; Patients with bone-only metastases; Patients with untreated active progressive CNS metastases – see trial for details; Patients with known BRCA1 or BRCA2 germline hereditary mutation(s)
https://ClinicalTrials.gov/show/NCT05128734